Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity

ALLEN, TX / ACCESSWIRE / January 16, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. has partnered with The Khalpey AI Lab to improve organ recovery, longevity, and the science of aging by combining drug development with artificial intelligence. This collaboration is a significant step in the biotechnology industry, aiming to reshape the complex biology of aging and organ regeneration. The partnership aims to use artificial intelligence to decode and transform the aging process, helping individuals live longer and healthier lives.

Understanding and combating aging and organ failure is a complex challenge involving genetic, epigenetic, and environmental factors. Enzolytics has formed a strategic alliance to address this challenge using its extensive data resources and AI analytics to develop innovative testing services. These services are expected to revolutionize medical science and offer new research opportunities.

The new approach will help scientists understand the aging process and organ failure. The Enzolytics team will leverage its advanced technology to introduce new testing services, promoting medical breakthroughs and making medical science more accessible. With developments made by the team, new horizons in medical research will be available to the public.

Enzolytics is driven by its powerful AI platform, which helps advance research on neurodegenerative diseases by analyzing intricate data related to nutrition, genetics, and microbiome. The Khalpey AI Lab complements this by introducing pioneering silico algorithms that revolutionize clinical diagnostics, risk assessment, and frailty evaluation in cardiovascular and oncological domains. The Khalpey AI Lab is committed to ethical AI governance, ensuring that its AI Ecosystem operates within a responsible and explainable AI framework, which enables it to translate advanced analytics into practical bedside applications.

Dr. Zain Khalpey, a renowned cardiac surgeon, stated, "The partnership between Enzolytics and our team is a significant milestone in developing medical therapies and optimizing patient care. This partnership focuses on identifying new biomarkers that can shed light on the aging process, going beyond the conventional approach of treating specific diseases.

Enzolytics, led by Dr. Gaurav Chandra, is pioneering an in-house AI Platform for Longevity. This innovative platform has two focuses:

1. The identification of therapeutic targets, and
2. Identifying biomarkers and exploring the potential of peptide bioregulators to stimulate the body's self-repair and rejuvenation processes. The AI-powered insights generated by this platform are expected to pave the way for groundbreaking discoveries in aging research."

Charles Cotropia, CEO of Enzolytics, said, "Enzolytics is dedicated to transforming healthcare by synergizing research, technology, and development to provide financially sustainable therapeutic solutions. Our commitment goes beyond partnerships, as we aim to make healthcare efficient, enduring, and accessible to those in need. Enzolytics is paving the way for a future where healthcare is within reach for everyone by advancing the application of AI through collaboration with experts in the field of AI technology."

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC.

While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of its therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.

Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.

Company Contact:
Enzolytics, Inc.
1101 Raintree Circle
Allen, Texas 75013
www.enzolytics.com

SOURCE: Enzolytics, Inc.